Jazz Pharmaceuticals vs Zoetis
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Jazz Pharmaceuticals and Zoetis side by side, using each one’s latest annual report. Here is what stands out:
- Zoetis is the larger business, with $9.5B of revenue in fiscal 2025 against $4.3B for Jazz Pharmaceuticals, about 2.2 times as much.
- Jazz Pharmaceuticals grew revenue faster (4.9%, against 2.3%).
- Jazz Pharmaceuticals turned more of its sales into free cash flow (30.4% FCF margin, against 24.1%).
- Zoetis earned a higher return on the capital invested in it (29.3%, against −4.2%).
- Investors pay more for each dollar of Jazz Pharmaceuticals’s earnings: a P/E of 14.1x against 13.3x for Zoetis.
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Jazz Pharmaceuticals
JAZZ
4/8
Revenue growth5-year growthFCF marginShare count change
Zoetis
ZTS
4/8
Net marginReturn on capitalReturn on equityPiotroski F-score
Side by side
Best in the row
| Latest fiscal year | JAZZ FY25 | ZTS FY25 |
|---|---|---|
| Size | ||
| Market cap | $14.3B | $33.8B |
| Revenue | $4.3B | $9.5B |
| Free cash flow | $1.3B | $2.3B |
| Net income | −$356M | $2.7B |
| Growth | ||
| Revenue growth | 4.9% | 2.3% |
| 5-year growth | 12.5% | 7.2% |
| Share count change | −7.6% | −2.4% |
| Profitability | ||
| Gross margin | — | 71.8% |
| Operating margin | −10.1% | — |
| Net margin | −8.4% | 28.2% |
| FCF margin | 30.4% | 24.1% |
| Return on capital | −4.2% | 29.3% |
| Return on equity | −8.5% | 66.0% |
| Balance sheet | ||
| Net debt | $4.0B | $6.7B |
| Net debt / EBITDA | — | 1.7x |
| Dividends and buybacks | $125M | $4.1B |
| Valuation & quality | ||
| P/E | 14.1x | 13.3x |
| Piotroski F-score | 4 | 8 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.